CHINA MEDICAL SYSTEM HOLDINGS LIMITED
康哲藥業控股有限公司*
(Incorporated in the Cayman Islands with Limited Liability)
(Hong Kong Stock Code: 867)
(Singapore Stock Code: 8A8)

Voluntary and Business Update Announcement
New Drug Application of Class 1 Innovative Drug Recombinant Fully Human Bispecific Antibody Against Rabies Virus Silevimig Injection Approved in China

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, "Silevimig Injection" or the "Product", trade name: 金速希®), a Class 1 therapeutic biological product has been approved by the National Medical Products Administration of the People's Republic of China ("NMPA") and the drug registration certificate was obtained on 22 June 2026. The Product is indicated for passive immunization in adults following rabies virus exposure.

Silevimig is a recombinant, fully human bispecific antibody against rabies virus ("RABV"). It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and III. Through this mechanism, Silevimig specifically neutralizes the RABV prior to the establishment of full protection by active rabies vaccination. The Product is the world's first bispecific antibody approved for passive immunization against rabies. Its molecular design is consistent with the recommendations of the World Health Organization ("WHO") for a "cocktail" combination formulation, to ensure broad effectiveness across different viral strains or genotypes. In a Phase III clinical trial in adults, the Product met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immune globulin ("HRIG"), the currently most used passive immunization product in China. The study confirmed that the Product provides immediate protection during the early stages of rabies virus exposure without compromising

* *For identification purpose only*

the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.

Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms, and progressive paralysis, with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective strategy. As vaccine-induced antibodies require 1 – 2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage. According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with Category II exposure involving severe immunodeficiency should receive passive immunization at the same time as the first dose of rabies vaccine. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization. Currently, the primary approved passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.

The Group continues to advance differentiated innovative products. The market for rabies passive immunization is substantial, yet existing passive immunization products are constrained by low market penetration and limitations in safety and accessibility. Silevimig Injection is the world's first fully human bispecific antibody targeting dual epitopes of the rabies virus, which is consistent with the WHO recommendation. The Product can be manufactured at scale with standardized processes, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunization, and controlled production cost. Moreover, it is the passive immunization product with the smallest dose for rabies, resulting in less injection volume and easier administration, which can effectively reduce patient pain and improve compliance. The approval of the Product will provide a new treatment option for patients requiring urgent post-exposure management against rabies in China, and is expected to synergize with the Group's existing expert network and market resources, thereby having a positive impact on the Group's overall business performance.

In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the "Agreement") with Chongqing Genrix Biopharmaceutical Co.,Ltd.. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the "Initial Term for the Product"). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.

The Group will promote the commercialization of the Product in an orderly manner to benefit patients with a new option for passive immunization against rabies at an early date.

The announcement is made on a voluntary basis. Shareholders and investors are advised to exercise caution in dealing in the shares and other securities of the Company.

By order of the Board
China Medical System Holdings Limited
Lam Kong
Chairman

Hong Kong, 22 June 2026

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong and Ms. Chen Yanling as executive directors; (ii) Mr. Leung Chong Shun, Ms. Luo Laura Ying and Mr. Fung Ching Simon as independent non-executive directors.